Catheter Precision (NYSEAMERICAN:VTAK) Issues Quarterly Earnings Results

Catheter Precision (NYSEAMERICAN:VTAK) released its earnings results on Friday. The company reported ($0.92) earnings per share for the quarter, beating the consensus estimate of ($19.00) by $18.08, FiscalAI reports. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.The firm had revenue of $1.02 million for the quarter, compared to the consensus estimate of $2.00 million.

Catheter Precision Trading Down 3.4%

Catheter Precision stock traded down $0.01 during midday trading on Friday, reaching $0.28. The stock had a trading volume of 673,619 shares, compared to its average volume of 4,579,099. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.35. Catheter Precision has a 52-week low of $0.23 and a 52-week high of $4.31. The firm has a market cap of $1.01 million, a price-to-earnings ratio of -0.02 and a beta of -1.00. The company has a fifty day moving average of $0.68 and a 200 day moving average of $1.05.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new stake in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 20.34% of the company’s stock.

Catheter Precision Company Profile

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.